LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world.
In March 2012, global pharmaceutical company Bayer was dealt a blow which would mark a significant turning point for the entire industry.
In India, the Controller of Patents issued the country’s first ever compulsory licence, forcing Bayer to license its patented cancer drug Nexavar (sorafenib) to Natco, a local generics company, which could then sell the drug at a cheaper price.
The controller said that Bayer, which celebrated its 150th anniversary in August, had not made Nexavar publicly available at a reasonably affordable price or sufficiently “worked the patent in India”.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Bayer, Jörg Thomaier, IP strategy, Nexavar, India